Edition:
India

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

37.15USD
4 Aug 2020
Change (% chg)

-- (--)
Prev Close
$37.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,250,451
52-wk High
$46.25
52-wk Low
$24.10

Latest Key Developments (Source: Significant Developments)

Boston Scientific Receives FDA Approval For Next-Generation Watchman Flx™ Left Atrial Appendage Closure Device
Wednesday, 22 Jul 2020 

July 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC RECEIVES FDA APPROVAL FOR NEXT-GENERATION WATCHMAN FLX™ LEFT ATRIAL APPENDAGE CLOSURE DEVICE.BOSTON SCIENTIFIC CORP - WILL IMMEDIATELY COMMENCE A LIMITED LAUNCH OF WATCHMAN FLX DEVICE IN U.S..  Full Article

Boston Scientific Prices Offerings Of Common Stock, Mandatory Convertible Preferred Stock
Friday, 22 May 2020 

May 21 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES OFFERINGS OF COMMON STOCK AND MANDATORY CONVERTIBLE PREFERRED STOCK.PRICING OF CONCURRENT OFFERINGS OF 25,550,000 SHARES OF ITS COMMON AT A PRICE TO PUBLIC OF $34.25 PER SHARE.PRICED 8.75 MILLION SHARES OF ITS 5.50% MANDATORY CONVERTIBLE PREFERRED STOCK, SERIES A AT A PRICE OF $100.00 PER SHARE.  Full Article

Boston Scientific Prices $1.7 Billion Of Senior Notes
Friday, 15 May 2020 

May 14 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES $1.7 BILLION OF SENIOR NOTES.BOSTON SCIENTIFIC - PUBLIC OFFERING CONSISTS OF $500.0 MILLION OF 1.900% NOTES DUE 2025 AND $1.2 BILLION OF 2.650% NOTES DUE 2030.  Full Article

Boston Scientific Sees Q4 Adjusted Earnings Per Share $0.42-$0.45
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR FY 2019 GAAP EARNINGS PER SHARE OF $0.72-$0.75 .BOSTON SCIENTIFIC - EXPECTS TO EXCEED PREVIOUS OUTLOOK FOR Q4 GAAP EARNINGS PER SHARE OF $0.22-$0.25 .SEES Q4 ADJUSTED EARNINGS PER SHARE $0.42-$0.45.BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR 2019.Q4 PRELIMINARY SALES $2.9 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.93 BILLION.Q4 EARNINGS PER SHARE VIEW $0.44, REVENUE VIEW $2.93 BILLION -- REFINITIV IBES DATA.ESTIMATES THAT IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.22 TO $0.25 FOR Q4.ESTIMATES IT WILL EXCEED ITS PREVIOUSLY ISSUED GUIDANCE FOR EARNINGS PER SHARE OF $0.72 TO $0.75 FOR FY 2019, ON A GAAP PER SHARE BASIS.BOSTON SCIENTIFIC - ESTIMATES ADJUSTED EARNINGS WILL BE WITHIN PREVIOUSLY ISSUED GUIDANCE RANGE OF $1.55 TO $1.58 PER SHARE FOR FULL YEAR 2019.ESTIMATES Q4 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), WILL BE WITHIN ITS PREVIOUSLY ISSUED GUIDANCE.FY2019 EARNINGS PER SHARE VIEW $1.57, REVENUE VIEW $10.76 BILLION -- REFINITIV IBES DATA.GENERATED PRELIMINARY FY 2019 SALES OF ABOUT $10.74 BILLION.  Full Article

Boston Scientific Prices €900 Mln Of Senior Notes
Thursday, 7 Nov 2019 

Nov 6 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PRICES €900,000,000 OF SENIOR NOTES.BOSTON SCIENTIFIC CORP - PRICING OF OFFERING OF EUR 900 MILLION OF 0.625% NOTES DUE 2027.  Full Article

Boston Scientific Announces FDA Approval Of Imageready Mri For Vercise Gevia Deep Brain Stimulation System
Tuesday, 20 Aug 2019 

Aug 19 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC ANNOUNCES FDA APPROVAL OF IMAGEREADY™ MRI FOR VERCISE GEVIA™ DEEP BRAIN STIMULATION SYSTEM.BOSTON SCIENTIFIC - VERCISE GEVIA DEEP BRAIN STIMULATION SYSTEM, VERCISE CARTESIA DIRECTIONAL LEAD IS DESIGNED TO TREAT PARKINSON'S DISEASE SYMPTOMS.  Full Article

Boston Scientific Says Submitted Borrowing Request For $2 Bln To Be Funded On Aug 19
Monday, 19 Aug 2019 

Aug 19 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC - SUBMITTED BORROWING REQUEST FOR $2.0 BILLION TO BE FUNDED ON AUG 19.BOSTON SCIENTIFIC CORP - FUNDS FROM DRAWDOWN WILL BE USED TO PARTIALLY FINANCE BOSTON SCIENTIFIC'S ACQUISITION OF BTG PLC.BOSTON SCIENTIFIC - BORROWINGS UNDER TWO-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE TWO YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - BORROWINGS UNDER THREE-YEAR DELAYED DRAW TERM LOAN CREDIT FACILITY WILL MATURE THREE YEARS FROM DATE OF CLOSING OF BTG ACQUISITION.BOSTON SCIENTIFIC - EXPECTS TO COMPLETE ANNOUNCED SALE OF GLOBAL EMBOLIC MICROSPHERES PORTFOLIO TO VARIAN MEDICAL SYSTEMS.  Full Article

BTG Says Boston Scientific Deal Cleared In U.S., Spain, Austria
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Boston Scientific Corp ::BTG, BOSTON SCIENTIFIC CONFIRM TRANSACTION RECEIVED MERGER CONTROL CLEARANCE FROM US FEDERAL TRADE COMMISSION.DEAL WITH BOSTON SCIENTIFIC ALSO CLEARED IN SPAIN, AUSTRIA.  Full Article

BTG Says Boston Scientific Signed Deal For Sale Of Existing Drug-Eluting & Bland Embolic Microsphere Business
Tuesday, 2 Jul 2019 

July 2 (Reuters) - BTG ::BTG - ON 1 JULY, BOSTON SCIENTIFIC SIGNED AGREEMENT FOR SALE OF EXISTING DRUG-ELUTING AND BLAND EMBOLIC MICROSPHERE BUSINESS.  Full Article

Late-Breaking Trial Data Highlight Continued Clinical Success Of Boston Scientific Emblem™ S-Icd System
Saturday, 11 May 2019 

May 10 (Reuters) - Boston Scientific Corp ::LATE-BREAKING TRIAL DATA HIGHLIGHT CONTINUED CLINICAL SUCCESS OF BOSTON SCIENTIFIC EMBLEM™ S-ICD SYSTEM.BOSTON SCIENTIFIC CORP - DATA DEMONSTRATED S-ICD THERAPY HAD A COMPLICATION-FREE RATE OF 95.8% AT 30 DAYS POST-PROCEDURE.BOSTON SCIENTIFIC CORP - DATA DEMONSTRATED S-ICD THERAPY HAD A HIGH CONVERSION EFFICACY (99.2%) OF INDUCED VENTRICULAR FIBRILLATION RATES.BOSTON SCIENTIFIC CORP - FINAL RESULTS OF UNTOUCHED STUDY WILL BE REPORTED AFTER 18-MONTHS OF PATIENT FOLLOW-UP.  Full Article

UPDATE 3-Boston Scientific sees improved July trends as elective surgery recovers

July 29 Medical device maker Boston Scientific Corp on Wednesday posted a surprise adjusted quarterly profit and said demand for elective procedures picked up pace in July following an easing of coronavirus-driven restrictions.